Oral calcium ameliorating oxaliplatin-induced peripheral neuropathy

Journal of Applied Research

Volumn 4, Issue 4, 2004, Pages 576-582

  Saif, Muhammad Wasif ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Calcium; Colon cancer; Magnesium; Neuropathy; Oxaliplatin

Indexed keywords

CALCIUM; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; DIAZEPAM; DIHYDROXYALUMINUM SODIUM CARBONATE; DIPHENHYDRAMINE; FLUOROURACIL; FOLINIC ACID; MAGNESIUM; MAGNESIUM OXIDE; OXALIPLATIN; RANITIDINE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON CANCER; DIARRHEA; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; MALE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRURITUS; TREATMENT OUTCOME;

EID: 11844271566     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Raymond E, Chaney SG, Taama A, et al. Oxaliplatin: A review of preclinical and clinical studies. Ann Oncol. 1998;9:1053-1071.
2. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
3. de Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214-219.
4. de Gramont A, Boni C, Navarro M. Tabernero J. Oxaliplatin/5FU/ LV in adjuvant colon cancer: safety results of the international randomized MOSAIC trial. Proc Am Soc Clin Oncol. 2002;21:132a.
5. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084-2091.
6. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767-1774.
7. Cannon SC. Ion-channel defects and aberrant excitability. In myotonia and periodic paralysis. Trends Neurosci. 1996;19:3-10.
8. Jacobsen D, Mc Martin KE. Methanol and ethylene glycol poisonings. Mechanisms of toxicity, clinical course, diagnosis and treatment. Med Toxicol. 1986;1:309-334.
9. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055-4061.
10. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol. 1998;25:13-22.
11. Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): Global safety in 682 patients. Proc Am Soc Clin Oncol. 1995;14:209. Abstract 513.
12. Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na (+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25-32.
13. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B. Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neural voltage-gated sodium channels. J Neurophysiol. 2001;85:2293-2297.
14. Sirois JE, Atchison WD. Effects of mercurial on ligand-and voltage-gated in channels: a review. Neurotoxicology. 1996;17:63-84.
15. + channel heterogeneity. Eur Neurol. 1996;36:3-12.
16. Andre T, Figer A, Cervantes A, et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc Am Soc Clin Oncol. 2003;22:253. Abstract 1016.
17. Eckel F, Schmelz R, Adelsberger H, Erdmann J, Quasthoff S, Lersch C. Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study. Dtsch Med Wochenschr. 2002;127:78-82.
18. Cascinu S, Catalano V, Cordella L, et al Neuroprotective effects of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478-3483.
19. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Scheithauer W. Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol. 2000;12:421-422.
20. Gedlicka C, Sheithauer W, Schull B, Kornek GV. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol. 2002;20(15):3359-3361.